

Marcus Unterrainer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6337684/publications.pdf>

Version: 2024-02-01

87
papers

1,758
citations

279798

23
h-index

345221

36
g-index

91
all docs

91
docs citations

91
times ranked

2296
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy±immune checkpoint inhibition. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1407-1416.	6.4	5
2	Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1417-1428.	6.4	13
3	⁶⁸ Ga-EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1711-1720.	6.4	15
4	Impact of Partial Volume Correction on [¹⁸ F]GE-180 PET Quantification in Subcortical Brain Regions of Patients with Corticobasal Syndrome. <i>Brain Sciences</i> , 2022, 12, 204.	2.3	2
5	Differential Spatial Distribution of TSPO or Amino Acid PET Signal and MRI Contrast Enhancement in Gliomas. <i>Cancers</i> , 2022, 14, 53.	3.7	12
6	Detection of Splenic Tissue Using ^{99m} Tc-Labelled Denatured Red Blood Cells Scintigraphy—A Quantitative Single Center Analysis. <i>Diagnostics</i> , 2022, 12, 486.	2.6	3
7	Amino Acid Uptake, Glucose Metabolism, and Neuroinflammation in John Cunningham Virus Associated Progressive Multifocal Leukoencephalopathy. <i>Clinical Nuclear Medicine</i> , 2022, Publish Ahead of Print, .	1.3	1
8	Longitudinal [¹⁸ F]GE-180 PET Imaging Facilitates In Vivo Monitoring of TSPO Expression in the GL261 Glioblastoma Mouse Model. <i>Biomedicines</i> , 2022, 10, 738.	3.2	8
9	Feasibility of [⁶⁸ Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3571-3580.	6.4	12
10	¹⁸ F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1208-1214.	5.0	2
11	Total Tumor Volume on ¹⁸ F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with ²²⁵ Ac-PSMA-I&T. <i>Biomedicines</i> , 2022, 10, 946.	3.2	6
12	Increased TSPO PET signal after radiochemotherapy in IDH-wildtype glioma—indicator for treatment-induced immune activation?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4282-4283.	6.4	7
13	PET/CT for Target Delineation of Lung Cancer Before Radiation Therapy. <i>Seminars in Nuclear Medicine</i> , 2022, , .	4.6	3
14	Simpson Grade Revisited — Intraoperative Estimation of the Extent of Resection in Meningiomas Versus Postoperative Somatostatin Receptor Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging. <i>Neurosurgery</i> , 2021, 88, 140-146.	1.1	27
15	Clinical impact of follicular oncocytic (H ¹⁴ rthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 449-460.	6.4	14
16	In Vivo Assessment of Neuroinflammation in ⁴ Repeat Tauopathies. <i>Movement Disorders</i> , 2021, 36, 883-894.	3.9	37
17	Transformation of diffuse large B cell lymphoma into dendritic sarcoma under CAR T cell therapy detected on ¹⁸ F-FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1692-1693.	6.4	2
18	Response to ²²⁵ Ac-PSMA-I&T after failure of long-term ¹⁷⁷ Lu-PSMA RLT in mCRPC. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1262-1263.	6.4	16

#	ARTICLE	IF	CITATIONS
19	The diagnostic challenge of coexistent sarcoidosis and thyroid cancer – a retrospective study. <i>BMC Cancer</i> , 2021, 21, 139.	2.6	7
20	Detection Gap of Right-Asymmetric Neuronal Degeneration by CERAD Test Battery in Alzheimer’s Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 611595.	3.4	2
21	Cost-Effectiveness Analysis of Local Ablation and Surgery for Liver Metastases of Oligometastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 1507.	3.7	15
22	PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC – current state and future directions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3975-3989.	6.4	25
23	TSPO PET imaging of natalizumab-associated progressive multifocal leukoencephalopathy. <i>Brain</i> , 2021, 144, 2683-2695.	7.6	13
24	Immature Plasma Cell Myeloma Mimics Metastatic Renal Cell Carcinoma on 18F-PSMA-1007 PET/CT Due to Endothelial PSMA-Expression. <i>Diagnostics</i> , 2021, 11, 423.	2.6	1
25	PSMA Expression in Glioblastoma as a Basis for Theranostic Approaches: A Retrospective, Correlational Panel Study Including Immunohistochemistry, Clinical Parameters and PET Imaging. <i>Frontiers in Oncology</i> , 2021, 11, 646387.	2.8	35
26	TERT-Promoter Mutational Status in Glioblastoma – Is There an Association With Amino Acid Uptake on Dynamic 18F-FET PET?. <i>Frontiers in Oncology</i> , 2021, 11, 645316.	2.8	4
27	Dosimetry and optimal scan time of [18F]SiTATE-PET/CT in patients with neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3571-3581.	6.4	15
28	Dual-Phase β -Amyloid PET Captures Neuronal Injury and Amyloidosis in Corticobasal Syndrome. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 661284.	3.4	13
29	Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders. <i>Life</i> , 2021, 11, 484.	2.4	11
30	Sarcoid-Like Reaction in Non-Hodgkin’s Lymphoma – A Diagnostic Challenge for Deauville Scoring on 18F-FDG PET/CT Imaging. <i>Diagnostics</i> , 2021, 11, 1009.	2.6	3
31	Feasibility of Different Tumor Delineation Approaches for 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 663631.	2.8	7
32	Cost-Effectiveness Analysis of Local Treatment in Oligometastatic Disease. <i>Frontiers in Oncology</i> , 2021, 11, 667993.	2.8	4
33	18F-FET PET Uptake Characteristics of Long-Term IDH-Wildtype Diffuse Glioma Survivors. <i>Cancers</i> , 2021, 13, 3163.	3.7	5
34	Molecular Imaging with 18F-FDG PET/CT and 99mTc-MIBI SPECT/CT in Osteitis Fibrosa Cystica Generalisata. <i>Diagnostics</i> , 2021, 11, 1355.	2.6	1
35	Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [18F]FET PET radiomics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4415-4425.	6.4	29
36	Diagnostic Accuracy of ^{68}Ga -PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection. <i>JAMA Oncology</i> , 2021, 7, 1635.	7.1	138

#	ARTICLE	IF	CITATIONS
37	Cognitive reserve hypothesis in frontotemporal dementia: A FDG-PET study. <i>NeuroImage: Clinical</i> , 2021, 29, 102535.	2.7	13
38	PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook. <i>Frontiers in Oncology</i> , 2021, 11, 774017.	2.8	10
39	Novel Multimodal Management of Post-Partum Synchronous Metastatic Pulmonary EBV-Associated Lymphoepithelioma-Like Carcinoma (LELC) – A Case Report. <i>Diagnostics</i> , 2021, 11, 2072.	2.6	2
40	Associations between sex, body mass index, and the individual microglial response in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
41	L-type amino acid transporter (LAT) 1 expression in 18F-FET-negative gliomas. <i>EJNMMI Research</i> , 2021, 11, 124.	2.5	13
42	Margin reduction in radiotherapy for glioblastoma through 18F-fluoroethyltyrosine PET? – A recurrence pattern analysis. <i>Radiotherapy and Oncology</i> , 2020, 145, 49-55.	0.6	23
43	Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2020, 35, 595-605.	3.9	42
44	TSPO PET With 18F-GE-180 to Differentiate Variants of Multiple Sclerosis. <i>Clinical Nuclear Medicine</i> , 2020, 45, e447-e448.	1.3	5
45	Longitudinal TSPO expression in tau transgenic P301S mice predicts increased tau accumulation and deteriorated spatial learning. <i>Journal of Neuroinflammation</i> , 2020, 17, 208.	7.2	19
46	Effects of the Minimal Extrathyroidal Extension on Early Response Rates after (Adjuvant) Initial Radioactive Iodine Therapy in PTC Patients. <i>Cancers</i> , 2020, 12, 3357.	3.7	8
47	18F-FDG PET/CT for Response Assessment in Pediatric Sebaceous Carcinoma of the Parotid Gland. <i>Diagnostics</i> , 2020, 10, 908.	2.6	1
48	Resting-state fMRI detects alterations in whole brain connectivity related to tumor biology in glioma patients. <i>Neuro-Oncology</i> , 2020, 22, 1388-1398.	1.2	60
49	Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2911-2922.	6.4	36
50	Dual PET Imaging of an H3K27M-Mutant Glioma With 18F-GE-180 and 18F-FET PET. <i>Clinical Nuclear Medicine</i> , 2020, 45, 992-993.	1.3	2
51	PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. <i>European Radiology Experimental</i> , 2020, 4, 63.	3.4	38
52	Clinical value of [18F]FDG-PET/CT and 3D-black-blood 3T-MRI for the diagnosis of large vessel vasculitis and single-organ vasculitis of the aorta. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 194-202.	0.7	6
53	Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas. <i>Neuro-Oncology</i> , 2019, 21, 274-284.	1.2	30
54	Neuronal injury biomarkers for assessment of the individual cognitive reserve in clinically suspected Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 24, 101949.	2.7	14

#	ARTICLE	IF	CITATIONS
55	Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic 18F-FET PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2581-2589.	6.4	34
56	Long-term outcome of rare oncocyctic papillary (H ¹⁴ rtle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2526-2535.	6.4	14
57	Longitudinal PET Monitoring of Amyloidosis and Microglial Activation in a Second-Generation Amyloid- β Mouse Model. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1787-1793.	5.0	41
58	Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation. <i>PLoS ONE</i> , 2019, 14, e0216111.	2.5	7
59	Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma. <i>Radiotherapy and Oncology</i> , 2019, 138, 99-105.	0.6	34
60	Comment on "Hypometabolic gliomas on FET-PET" is there an inverted U-curve for survival? <i>Neuro-Oncology</i> , 2019, 21, 1612-1613.	1.2	9
61	Teaching NeuroImages: Advanced imaging of neurosarcooidosis with ⁶⁸ Ga-DOTATATE PET/CT. <i>Neurology</i> , 2019, 92, e2512-e2513.	1.1	4
62	Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patients. <i>Neuro-Oncology</i> , 2019, 21, 1331-1338.	1.2	31
63	First-in-Human Brain Imaging of [¹⁸ F]TRACK, a PET tracer for Tropomyosin Receptor Kinases. <i>ACS Chemical Neuroscience</i> , 2019, 10, 2697-2702.	3.5	19
64	In response to: The validity of 18F-GE180 as a TSPO imaging agent. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1208-1211.	6.4	19
65	Identification of Distant Metastases From Recurrent Gliosarcoma Using Whole-Body 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2019, 44, 923-924.	1.3	2
66	Comparison of 18F-GE-180 and dynamic 18F-FET PET in high grade glioma: a double-tracer pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 580-590.	6.4	52
67	TSPO PET with [18F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing/remitting multiple sclerosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1423-1431.	6.4	53
68	Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. <i>Neuro-Oncology</i> , 2018, 20, 279-288.	1.2	71
69	Coupling between physiological TSPO expression in brain and myocardium allows stabilization of late-phase cerebral [18F]GE180 PET quantification. <i>NeuroImage</i> , 2018, 165, 83-91.	4.2	27
70	Voxel-wise analysis of dynamic 18F-FET PET: a novel approach for non-invasive glioma characterisation. <i>EJNMMI Research</i> , 2018, 8, 91.	2.5	20
71	Imaging microglial activation in tacrolimus-associated CNS vasculitis with translocator protein PET. <i>Neurology</i> , 2018, 91, 936-937.	1.1	6
72	IgLON5: A case with predominant cerebellar tau deposits and leptomeningeal inflammation. <i>Neurology</i> , 2018, 91, 180-182.	1.1	23

#	ARTICLE	IF	CITATIONS
73	Clinical Routine FDG-PET Imaging of Suspected Progressive Supranuclear Palsy and Corticobasal Degeneration: A Gatekeeper for Subsequent Tau-PET Imaging?. <i>Frontiers in Neurology</i> , 2018, 9, 483.	2.4	21
74	Detection of Cerebrospinal Fluid Dissemination of Recurrent Glioblastoma Using TSPO-PET With 18F-GE-180. <i>Clinical Nuclear Medicine</i> , 2018, 43, 518-519.	1.3	18
75	Data on specificity of [18F]GE180 uptake for TSPO expression in rodent brain and myocardium. <i>Data in Brief</i> , 2018, 19, 331-336.	1.0	4
76	18F-FET PET prior to recurrent high-grade glioma re-irradiation—additional prognostic value of dynamic time-to-peak analysis and early static summation images?. <i>Journal of Neuro-Oncology</i> , 2017, 132, 277-286.	2.9	21
77	Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2239-2248.	6.4	15
78	The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients?. <i>Neuro-Oncology</i> , 2017, 19, 1698-1699.	1.2	19
79	Epidural Metastases From Follicular Thyroid Cancer Mimicking Meningiomas in 68Ga-DOTATATE PET. <i>Clinical Nuclear Medicine</i> , 2017, 42, 805-806.	1.3	10
80	Towards standardization of 18F-FET PET imaging: do we need a consistent method of background activity assessment?. <i>EJNMMI Research</i> , 2017, 7, 48.	2.5	76
81	TSPO imaging using the novel PET ligand [18F]GE-180: quantification approaches in patients with multiple sclerosis. <i>EJNMMI Research</i> , 2017, 7, 89.	2.5	55
82	In Vivo Imaging of Glial Activation after Unilateral Labyrinthectomy in the Rat: A [18F]GE180-PET Study. <i>Frontiers in Neurology</i> , 2017, 8, 665.	2.4	15
83	18F-FET PET Uptake Characteristics in Patients with Newly Diagnosed and Untreated Brain Metastasis. <i>Journal of Nuclear Medicine</i> , 2017, 58, 584-589.	5.0	36
84	Monitoring of Tumor Growth with [18F]-FET PET in a Mouse Model of Glioblastoma: SUV Measurements and Volumetric Approaches. <i>Frontiers in Neuroscience</i> , 2016, 10, 260.	2.8	13
85	Serial ¹⁸ F-FET PET Imaging of Primarily ¹⁸ F-FET—Negative Glioma: Does It Make Sense?. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1177-1182.	5.0	56
86	Suspected recurrence of brain metastases after focused high dose radiotherapy: can [18F]FET- PET overcome diagnostic uncertainties?. <i>Radiation Oncology</i> , 2016, 11, 139.	2.7	59
87	Implementation of the European multicentre database of healthy controls for [123I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1315-1322.	6.4	29